Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $39.20 Consensus PT from Analysts

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $39.20.

SYRE has been the topic of several research analyst reports. Stifel Nicolaus boosted their price objective on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Wells Fargo & Company raised shares of Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $12.00 to $35.00 in a research note on Friday, March 1st.

Spyre Therapeutics Stock Down 1.6 %

NASDAQ:SYRE opened at $32.47 on Tuesday. The company has a 50-day moving average price of $34.51. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -0.43 and a beta of 2.88. Spyre Therapeutics has a 1-year low of $2.66 and a 1-year high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($2.28) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($1.80). Sell-side analysts anticipate that Spyre Therapeutics will post -2.36 EPS for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).